drug development

Biotech, Pharma & Cancer Drug Development

Expedition Therapeutics Secures $115 Million Series B to Advance Novel Lung Disease Therapy, Reinforcing Trend of China-Originated Drug Development

Expedition Therapeutics, a rapidly emerging biotechnology company focused on bringing innovative therapies to market, announced...

Biotech, Pharma & Cancer Drug Development

Biopharmaceutical Sector Witnesses Executive Transition at J&J, Mixed Clinical Outcomes, Strategic Alliances, and Expanded Drug Approvals

admin Aug 5, 2026

The biopharmaceutical landscape has recently been marked by a series of significant developments, including a...

Biotech, Pharma & Cancer Drug Development

Pfizer Expands Cost-Cutting Initiative to $6.5 Billion Amidst Post-Pandemic Revenue Adjustments and Pipeline Challenges

admin Aug 5, 2026

New York, NY – August 4, 2026 – Pfizer Inc. today announced a significant expansion...

Biotech, Pharma & Cancer Drug Development

Vertex Pharmaceuticals Navigates Robust Financial Growth Amidst Emerging Competitive Threats in Cystic Fibrosis Market

admin Aug 4, 2026

Vertex Pharmaceuticals, a titan in the biotechnology sector, recently reported stellar financial results for the...

Biotech, Pharma & Cancer Drug Development

Resilience and Lilly invest $750M to boost Cincinnati drug production

admin Aug 4, 2026

In a significant move to bolster the production of critical GLP-1 injectable medications, contract manufacturer...

Biotech, Pharma & Cancer Drug Development

Supernus Pharmaceuticals to Acquire Indivior in a Strategic Merger Creating a Diversified Neurological and Psychiatric Powerhouse

admin Aug 4, 2026

In a significant move poised to reshape the specialty pharmaceutical landscape, Supernus Pharmaceuticals has announced...

Biotech, Pharma & Cancer Drug Development

BioNTech Appoints Guido Oelkers as New CEO, Solidifying Oncology Re-focus as Co-Founders Depart for New mRNA Venture

admin Aug 4, 2026

BioNTech, the German biotechnology firm that rose to global prominence for its pioneering COVID-19 vaccine,...

Biotech, Pharma & Cancer Drug Development

AstraZeneca and Bristol Myers Squibb Megamerger Rumors Trigger Market Turmoil and Industry Rethink

admin Aug 3, 2026

Rumors of a potential megamerger between pharmaceutical giants AstraZeneca and Bristol Myers Squibb have sent...

Biotech, Pharma & Cancer Drug Development

Trump administration tries again to institute rebates in 340B

admin Aug 3, 2026

The Trump administration has once again initiated a pilot program aimed at implementing rebates within...

Biotech, Pharma & Cancer Drug Development

Sanofi Seeks to Reinvigorate Regeneron Alliance Amid Strategic Reshuffle, While BMS Faces Pipeline Delays and Apnimed’s IPO Signals Biotech Resilience

admin Aug 1, 2026

A dynamic week in the biopharmaceutical sector saw Sanofi’s new leadership publicly commit to mending...

Breaking

Expedition Therapeutics Secures $115 Million Series B to Advance Novel Lung Disease Therapy, Reinforcing Trend of China-Originated Drug Development

Biopharmaceutical Sector Witnesses Executive Transition at J&J, Mixed Clinical Outcomes, Strategic Alliances, and Expanded Drug Approvals

Pfizer Expands Cost-Cutting Initiative to $6.5 Billion Amidst Post-Pandemic Revenue Adjustments and Pipeline Challenges

Vertex Pharmaceuticals Navigates Robust Financial Growth Amidst Emerging Competitive Threats in Cystic Fibrosis Market

Resilience and Lilly invest $750M to boost Cincinnati drug production

Supernus Pharmaceuticals to Acquire Indivior in a Strategic Merger Creating a Diversified Neurological and Psychiatric Powerhouse

BioNTech Appoints Guido Oelkers as New CEO, Solidifying Oncology Re-focus as Co-Founders Depart for New mRNA Venture

AstraZeneca and Bristol Myers Squibb Megamerger Rumors Trigger Market Turmoil and Industry Rethink

Trump administration tries again to institute rebates in 340B

Sanofi Seeks to Reinvigorate Regeneron Alliance Amid Strategic Reshuffle, While BMS Faces Pipeline Delays and Apnimed’s IPO Signals Biotech Resilience

Alumis’s Envudeucitinib Fails to Meet Primary Endpoints in Phase 2b Lupus Trial, Shares Plunge Amid Broader TYK2 Inhibitor Challenges

Novartis’s Remibrutinib Emerges as a Differentiated BTK Inhibitor, Evading Liver Safety Concerns Plaguing Rivals in the Autoimmune Landscape

Brazilian Research Identifies Molecular Mechanisms of Early Nerve Invasion in Pancreatic Cancer Offering New Targets for Precision Medicine

Stanford Medicine Pioneers Revolutionary Antibody Therapy, Eliminating Toxic Conditioning for Stem Cell Transplants

Breakthrough in Personalized Oncology: German and Chinese Scientists Develop IPTO Model to Revolutionize Brain Tumor Treatment and Drug Testing

Alumis’s Envudeucitinib Fails to Meet Primary Endpoints in Phase 2b Lupus Trial, Shares Plunge Amid Broader TYK2 Inhibitor Challenges

Novartis’s Remibrutinib Emerges as a Differentiated BTK Inhibitor, Evading Liver Safety Concerns Plaguing Rivals in the Autoimmune Landscape

Brazilian Research Identifies Molecular Mechanisms of Early Nerve Invasion in Pancreatic Cancer Offering New Targets for Precision Medicine

Stanford Medicine Pioneers Revolutionary Antibody Therapy, Eliminating Toxic Conditioning for Stem Cell Transplants

Alumis’s Envudeucitinib Fails to Meet Primary Endpoints in Phase 2b Lupus Trial, Shares Plunge Amid Broader TYK2 Inhibitor Challenges

Novartis’s Remibrutinib Emerges as a Differentiated BTK Inhibitor, Evading Liver Safety Concerns Plaguing Rivals in the Autoimmune Landscape

Brazilian Research Identifies Molecular Mechanisms of Early Nerve Invasion in Pancreatic Cancer Offering New Targets for Precision Medicine

Stanford Medicine Pioneers Revolutionary Antibody Therapy, Eliminating Toxic Conditioning for Stem Cell Transplants

Alumis’s Envudeucitinib Fails to Meet Primary Endpoints in Phase 2b Lupus Trial, Shares Plunge Amid Broader TYK2 Inhibitor Challenges

Novartis’s Remibrutinib Emerges as a Differentiated BTK Inhibitor, Evading Liver Safety Concerns Plaguing Rivals in the Autoimmune Landscape

Brazilian Research Identifies Molecular Mechanisms of Early Nerve Invasion in Pancreatic Cancer Offering New Targets for Precision Medicine

Stanford Medicine Pioneers Revolutionary Antibody Therapy, Eliminating Toxic Conditioning for Stem Cell Transplants

You Missed

Alumis’s Envudeucitinib Fails to Meet Primary Endpoints in Phase 2b Lupus Trial, Shares Plunge Amid Broader TYK2 Inhibitor Challenges

Novartis’s Remibrutinib Emerges as a Differentiated BTK Inhibitor, Evading Liver Safety Concerns Plaguing Rivals in the Autoimmune Landscape

Brazilian Research Identifies Molecular Mechanisms of Early Nerve Invasion in Pancreatic Cancer Offering New Targets for Precision Medicine

Stanford Medicine Pioneers Revolutionary Antibody Therapy, Eliminating Toxic Conditioning for Stem Cell Transplants